TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control

Trial Profile

TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Acronyms TECOS
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 08 Jan 2018 Results of post hoc analysis assessing association between Severe Hypoglycemic Events and cardiovascular events published in the Diabetes Care
    • 08 Dec 2017 Results of analysis evaluating severe hypoglycaemic events and cardiovascular outcomes and their association with each other presented at the 2017 Congress of the International Diabetes Federation
    • 01 Nov 2017 Results (n=12,275) assessing association between baseline SBP and recurrent cardiovascular disease, were published in the Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top